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1. Introduction 
The dietary intake of polyunsaturated fatty acids (PUFA) has a significant effect on blood and 
tissue PUFA content (1, 2). Tissue availability of PUFA, which depends on both diet and 
metabolic turnover, has a major impact on human health (3-5). Adequate fatty acid (FA) 
intake is very important in every stage of life, but particularly for the fetus and neonate to 
enable optimal visual and cognitive development (6, 7). Biomarkers of FA status are widely 
used in observational studies, as they reflect a combination of dietary intake and metabolism. 
Associations of FA status with current and future health indicators have been demonstrated 
(8, 9). Epidemiological and clinical studies have revealed associations between FA and 
cardiovascular diseases, diabetes, and certain types of cancer (10-12). 
Analysis of FA composition in different blood and lipid fractions seems to be a valuable 
biomarker to assess the FA status in humans (8-10). Depending on the scientific question the 
FA composition can be determined in adipose tissue, erythrocytes, plasma, platelets, whole 
blood, and specific cells or tissues. Adipose tissue, as the main storage compartment for FA 
in humans, is considered a good long term biomarker for FA intake, because of the slow 
turnover time (8, 13). However, in large clinical trials and epidemiological studies, blood 
collection is easier and less invasive than tissue collection.  
The most convenient way to asses FA composition is whole blood analysis, because 
separation of plasma and lipid fractions is not required and dried blood spots have been 
shown as suitable for analysis (14, 15). This simplifies study logistics considerably as the 
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need of immediate sample freezing is avoided. However, the procedure is not yet well 
established (14, 16, 17) and data interpretation seems more difficult, because different 
influencing factors have to be considered. A crucial influencing factor is hematocrit, the 
proportion of blood volume that is occupied by red blood cells. The hematocrit depends on 
gender (18) and age, e.g. hematocrit is higher in neonates than adults and decreases during 
the first months of life (19). The hematocrit may be altered by factors such as hypertension 
(18), pulmonary and cardiac diseases, and pregnancy (20). Variation of the hematocrit may 
lead to misinterpretation of whole blood FA data because the FA composition of plasma and 
red blood cells, the main components of whole blood, differs significantly (21). 
Very specific information on FA status can be obtained by analyzing the FA composition in an 
individual lipid fraction of serum or plasma, which minimizes the influence of factors such as 
postprandial state and individual lipid metabolism. Conventional methods consist of several 
analytical steps and are therefore cumbersome and time-consuming. Typically a skilled 
chemist requires 2 days for analyzing 10-20 samples (22). For studies focusing on long chain 
polyunsaturated fatty acids (LC-PUFA) it seems most promising to analyze plasma 
phospholipids (PL), because they contain higher percentages of LC-PUFA and are less 
sensitive to short term variation than plasma non esterified fatty acids (NEFA), 
triacylglycerides (TAG) and cholestryl esters (CE) (23, 24). For the determination of PL FA in 
biological samples Bondia-Pons et al. (25) presented an optimized method for lipid extraction 
and lipid separation using solid phase extraction instead of thin layer chromatography. Their 
sample preparation technique is easier than those of established methods, but it is still very 
time-consuming.  
1. INTRODUCTION 
 
 3 
The term phospholipid is used for all lipids with a phosphorus-containing polar head group. PL 
can be further subdivided in glycerophospholipids (GP) and phosphospingolipids (SM), based 
on their glycerole or sphingoid base backbone, respectively. The major PL fractions in plasma 
are glycerophosphocholines and SM (26, 27). While LC-PUFA percentages are high in 
glycerophosphocholines and other GP, LC-PUFA contribute less than 5 % to the FA esterified 
to sphingosine in SM (26, 28). The contribution of SM to total plasma PL varies widely in 
healthy controls and in patients suffering from coronary artery disease (27). Thus, a further 
source of variation in LC-PUFA percentages can be eliminated by determining selectively the 
FA composition of GP, while excluding SM from FA analysis. One objective of this 
dissertation was to develop a high-throughput method for the analysis of GP FA composition 
in plasma and serum.  
Although analysis of FA composition in defined lipid fraction is considered optimal, analysis of 
total plasma lipids can be a suitable alternative, if fasted blood samples are available and 
precise quantification of intervention effects is not needed. The plasma total FA pool 
represents a mixture of all plasma lipid fractions that contain FA moieties, in particular CE, 
NEFA, PL, and TAG. The FA composition is typical for each lipid class, and different FA 
compete for the incorporation in individual plasma lipid classes. Thus, analysis of the total FA 
pool offers the opportunity to determine overall changes in plasma FA status. It has to be 
considered that variation in the contribution of lipid fractions modify total plasma FA 
composition even if FA composition within the fraction does not change. Nevertheless, if 
methods are robust, total lipid FA analysis can provide valuable information in a cost effective 
way. 
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Lepage and Roy (29) developed the first direct transesterification method to assess total FA 
composition in plasma. They performed transesterification with acetyl chloride in methanol-
benzol (4:1) at 100 °C for 1h, followed by neutralization and centrifugation. Masood, Stark and 
Salem (30) presented in 2005 a simplified version of the original method of Lepage and Roy. 
In 2008 Masood and Salem (22) published a modified version of this method, which enables a 
half automated sample preparation, but the reaction time is very long and large amounts of 
solvents are used.  
A further objective of this dissertation was to simplify the assessment of total lipid FA 
composition in plasma with as few sample preparation steps as possible to enable its 
application in large studies. Furthermore, to confine consumable, reagent and solvent 
requirements to a minimum and perform all preparation steps in one vial. 
Clinical and epidemiological studies showed that an adequate availability of PUFA is 
necessary for normal growth as well as normal visual, cognitive and immune functions in 
infants and children (31-33). Monitoring of FA status may be indicated in children with 
modified dietary FA intake (e.g. in some patients with parenteral nutrition), or with disease 
related alterations of absorption or metabolism (e.g. in patients with short bowel syndrome, 
inflammatory bowel disease, metabolic liver disease), and or with interventions such as fish 
oil supplementation in children with phenylketonuria or other inborn errors of amino acid 
metabolism to monitor the intervention effects (6, 33-36). Monitoring of FA status in individual 
patients or in populations depends on the availability of reference values obtained in healthy 
children to allow interpretations of the results obtained. Thus, the availability of reference 
values is a prerequisite for interpreting FA status of individuals. The newly developed high-
throughput method was used to analyze the GP FA composition in 1326 serum samples 
1. INTRODUCTION 
 
 5 
obtained from 951 children aged 2 and 6 years who participated in a birth cohort study. The 
data were used to establish reference values for GP FA composition in children.  
The concentrations of individual FA in plasma and tissues do not evolve independently, but 
rather mutually influence each other as they compete for incorporation into lipids. 
Consequently the percentage FA composition of specific compartments is widely used for the 
description of FA status. Although analyses of FA status are successfully applied for the 
evaluation of dietary intake (13), FA status is influenced by both diet and endogenous 
metabolism. In several studies strong associations were found between variants in the human 
genes fatty acid desaturase 1 (FADS1) and fatty acid desaturase 2 (FADS2) and blood levels 
of PUFA (37-39). The importance of endogenous metabolism is even greater for LC-PUFA 
than for the saturated and monounsaturated FA which can be synthesized de novo by human 
metabolism (40).  
Another important aspect, when evaluating a biomarker, is temporal variability, which 
depends on the turnover of the compartment. Thus, the composition of plasma lipids varies 
within days or weeks, whereas significant changes of FA composition in adipose tissue are 
only observed after months (13). As plasma lipids can change within short periods, an 
investigation of the tracking of FA status over years yields information on longer term changes 
of dietary habits and life style factors. In adults it has been shown that FA composition of 
plasma CE and PL showed a high tracking with coefficients of correlation between FA 
percentages up to 0.83 (41, 42). Similar values were observed in total plasma PL of a small 
group of Portuguese children (n = 26), but this observation might depend very much on the 
given cultural and socioeconomic situation of that sample (43). The aim of this work was to 
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reevaluate these finding of Guerra et al. in a population-based sample of children considering 
additionally the potential influence of different FADS gene variants. 
This work is intended to provide new sophisticated methods for sensitive high-throughput FA 
analysis in human blood plasma and serum. The goal is to develop markedly simplified 
approaches to preanalytical sample preparation, which currently is a very time consuming and 
hence expensive factor, limiting the number of subjects that can be studied for clinical and 
research questions. The newly developed methodological approaches should allow for fast 
and cost effective yet sensitive and precise measurements from small sample volumes, which 
should allow the application in large clinical studies even in infants and young children. The 
objectives of this work are as follows: 
• Development of a method for high-throughput analysis of GP FA composition in 
plasma. 
• Validation of the suitability to analyze GP FA composition in serum with the new 
method. 
• Determination of GP FA compositions in children to provide reference values. 
• Investigation of the tracking of serum GP FA concentrations and percentage 
composition in children. 
• Evaluation of the influence of FADS polymorphisms on tracking of FA in children. 
• Development of a method for high-throughput analysis of plasma total lipid FA 
composition. 
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This dissertation is based on the following published or submitted articles: 
1. Review: 
 Glaser C, Heinrich J, Koletzko B. Role of FADS1 and FADS2 polymorphisms in 
polyunsaturated fatty acid metabolism. Metabolism 2010, 59:993-9. 
2. Research article: 
 Glaser C, Demmelmair H, Koletzko B. High-throughput analysis of fatty acid composition 
of plasma glycerophospholipids. J Lipid Res 2010, 51:216-21. 
3. Research article: 
 Glaser C, Demmelmair H, Sausenthaler S, Herbarth O, Heinrich J, Koletzko B. Fatty acid 
composition of serum glycerophospholipids in children. J Pediatr 2010, 157:826-31. 
4. Research article: 
 Glaser C, Demmelmair H, Rzehak P, Klopp N, Heinrich J, Koletzko B. Influence of FADS 
polymorphisms on tracking of serum glycerophospholipid fatty acid concentrations and 
percentage composition in children. submitted. 
5. Research article: 
 Glaser C, Demmelmair H, Koletzko B. High-throughput analysis of total plasma fatty acid 
composition with direct in situ transesterification. PLoS ONE 2010, 5(8):e12045. 
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Abstract (222 words) 
Background: Tracking of fatty acid (FA) contribution to plasma or serum lipids over time was 
shown in children and adults. However, the potential role of FADS gene variants has not been 
investigated. 
Methods and Principal Findings: Serum GP FA composition of 331 children aged 2 and 6 
years, participating in an ongoing birth cohort study, was analyzed. Correlation coefficients 
were estimated to describe FA tracking over 4-years and to assess the influence of FADS 
variants on tracking. We found low to moderate tracking (r = 0.12 - 0.49) of FA compositions 
and concentration between 2 and 6 years. Concentration changes of total monounsaturated 
FA and total saturated FA over time correlated closely (r = 0.79) but percentage values were 
unrelated (r = -0.02). Tracking for n-6 long chain polyunsaturated fatty acid (LC-PUFA) 
concentrations was lower in subjects homozygous for the major allele of FADS variants and 
higher in carriers of at least one minor allele, whereas for total n-3 LC-PUFA concentrations 
and compositions this was vice versa. For individual n-3 PUFA inconsistent results were 
found. 
Conclusions and Significance: Serum GP FA composition shows low to moderate tracking 
over 4-years with a higher tracking for LC-PUFA metabolites than for their precursor FA. 
Serum PUFA levels and their tracking seem to be more influenced by lipid and lipoprotein 
metabolism than by FA specific pathways. 
 
Key Words: arachidonic acid, children, docosahexaenoic acid, FADS1 FADS2 gene cluster, 
polyunsaturated fatty acids 
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Introduction 
Biomarkers of fatty acid (FA) status are widely used in observational studies. They reflect a 
combination of dietary intake and metabolism. Associations of FA status with current and 
future health indicators have been demonstrated [1-2]. Epidemiological and clinical studies 
have revealed associations between FA and cardiovascular diseases, diabetes, and certain 
types of cancer [3-5].  
The concentrations of individual FA in plasma and tissues do not evolve independently, but 
rather mutually influence each other. As individual FA are preferentially partitioned into 
specific lipid pools [6], the percentage FA composition of specific compartments is widely 
used to describe FA status. Although analyses of FA status are successfully applied for the 
evaluation of dietary intake [7], FA status is influenced by both diet and endogenous 
metabolism. In several studies strong associations were found between variants in the human 
genes fatty acid desaturase 1 (FADS1) and fatty acid desaturase 2 (FADS2) and blood levels 
of polyunsaturated fatty acids (PUFA) [8-13]. These associations clearly indicate an influence 
of endogenous metabolism on the blood levels of essential FA. The importance of 
endogenous metabolism is even greater for long chain polyunsaturated fatty acids (LC-PUFA) 
than for the saturated and monounsaturated FA which can be synthesized de novo by human 
metabolism [14].  
FA status and in particular the balance of n-3 and n-6 LC-PUFA have been related to long 
term health [15-16]. LC-PUFA have been demonstrated in all lipid compartments considered 
so far as indicative of human FA status. Their concentrations are highest in 
glycerophospholipids (GP), which suggests their suitability for describing sensitively FA status 
including LC-PUFA status. Due to the differences of LC-PUFA concentrations in different 
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compartments (e.g. plasma lipid fractions), analysis of defined, purified fractions is mandatory 
in order to avoid misleading results. 
Another important aspect when evaluating a biomarker is temporal variability, which depends 
on the turnover of the compartment. The composition of plasma lipids varies within days or 
weeks, whereas significant changes of FA composition in adipose tissue are only observed 
after months [7]. As plasma lipid composition may change within short periods, an 
investigation of the tracking of plasma lipid FA status over years yields information on longer 
term changes of dietary habits and life style factors. In adults it has been shown that FA 
composition of plasma cholesteryl esters and phospholipids showed a high degree of 
tracking, with coefficients of correlation between FA percentages up to 0.83 [17-18]. Similar 
values were observed in total plasma phospholipids of a small group of Portuguese children 
(n = 26). However, this observation might be very much influenced by the given cultural and 
socioeconomic conditions of this particular group of children [19]. 
We aimed to reevaluate the findings of Guerra et al. [19] in a larger, population-based sample 
of children. Furthermore, we aimed to investigate the influence of polymorphisms in the FADS 
gene cluster on FA tracking which has not been investigated so far. 
According to current knowledge, the carriers of the major alleles of the 5 studied SNPs 
(rs174545, rs174546, rs174556, rs174561, rs3834458) should have a higher conversion of 
LA and ALA to their corresponding derivates than carriers of at least one minor allele [8,11-
12]. We hypothesized that carriers of the major allele would show a greater stability of LC-
PUFA values over time and therefore show a greater degree of LC-PUFA tracking than 
carriers of at least one minor allele. 
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Methods 
Ethics statement 
For this study, approval by the respective local Ethics Committees (Bavarian General Medical 
Council, University of Leipzig, Medical Council of North-Rhine-Westphalia) and written 
informed consent from the families (parents) of participants were obtained. 
 
Study design and population 
The LISA study (“Influences of Lifestyle related Factors on the Immune System and the 
Development of Allergies in Childhood”) is an ongoing population-based birth cohort study of 
unselected newborns. The design of this study has been described elsewhere before [20-21]. 
Between November 1997 and January 1999, 3097 healthy full-term newborns were recruited 
in Munich (n=1467), Leipzig (n=976), Wesel (n=306), and Bad Honnef (n=348). Neonates 
were excluded if at least one of the following exclusion criteria was present: preterm birth 
(maturity < 37 gestational week), low birth weight (< 2500 g), congenital malformation, 
symptomatic neonatal infection, antibiotic medication, hospitalisation or intensive medical 
care during neonatal period. In addition to lack of consent to participate in this study, 
newborns from mothers with immune-related diseases such as autoimmune disorders, 
diabetes, hepatitis B, long-term medication or abuse of drugs and alcohol, and newborns from 
parents with a nationality other than German and parents who were not born in Germany 
were excluded. 
We collected questionnaire data on family history of atopy, parental education and health 
problems during pregnancy, smoking of the mother during pregnancy and mothers’ exposure 
to environmental tobacco smoke during pregnancy at home. The cohort was followed up at 
5. PUBLICATION 4 
 
 46 
the ages of 6, 12 and 18 months, and 2, 4, 6 and 10 years. Blood samples were collected at 
birth (cord blood) and from the children at 2, 6 and 10 years.  
For the present analyses, only data from the 2- and 6-year follow-up of study center Munich 
(n=1331 and n=1172, respectively) were included. Serum samples both at the age of 2 and 6 
years were available for analysis in 375 children (213 boys, 162 girls). Both genotyping data 
and fatty acid data were available for 331 children. Figure 1 shows the origin of the samples.  
 
Fatty acid analysis 
Venous blood samples were collected in serum separator tubes and centrifuged. Serum was 
frozen in plastic vials and stored at -80 °C until analysis. Glycerophospholipid FA were 
analyzed as described earlier [22]. Briefly, 100 µl of internal standard (1,2-dipentadecanoyl-
sn-glycero-3-phosphocholine dissolved in methanol) and 0.6 ml methanol were added to 100 
µl of serum, and samples were shaken for 30 s. After centrifugation the supernatant was 
transferred into another glass tube. Twenty-five µl of sodium methoxide solution were added 
and tubes were shaken for synthesis of fatty acid methyl esters (FAME). The 
transesterification was stopped after 3 min by adding 75 µl methanolic HCl. FAME were 
extracted twice with 300 µl hexane each. Extracts were combined and dried under nitrogen 
flow at room temperature. The residue was taken up in 50 µl hexane (containing 2 g/l 
butylated hydroxy toluene) and analyzed by gas chromatography (GC). 
We used GC with flame ionization detection for quantifying the FAME. Individual FAME were 
identified by comparison with authentic standards (GLC-569B, Nu-Check Prep, Inc., Elysian, 
MN, USA; cis-5,8,11-eicosatrienoic acid methyl ester, Sigma-Aldrich, Taufkirchen, Germany; 
methyl vaccenate (11c), methyl octadecatetraenoate (6c, 9c, 12c, 15c) and methyl brassidate 
(13tr), Larodan Fine Chemicals AB, Malmö, Sweden). We used the general designations 
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C16:1t, C18:1t, C18:2tt and C22:1t in the results section because we cannot exclude that 
different isomeric trans FA coelute.  
As external standard GLC-85 (Nu-Check Prep, Inc., Elysian, MN, USA) was used for 
determining the response relative to pentadecanoic acid methyl ester (internal standard). For 
peak integration EZChrom Elite version 3.1.7 (Agilent, Waldbronn, Germany) was used.  
 
Genotyping 
Genomic DNA was extracted from EDTA blood using standard methods and amplified by 
using REPLI-g UltraFast technology (Qiagen™). Five variants of the FADS1 FADS2 gene 
cluster (rs174545, rs174546, rs174556, rs174561, rs3834458) were typed, which have been 
previously shown to be in strong linkage disequilibrium with each other [8,11]. SNPs were 
selected based on previous publications [8,11-12]. Applying the tagger server program 
(http://www.broadinstitute.org/mpg/tagger/) in combination with HapMap we found that with 
the 3 SNPs rs174545, rs174546 and rs174556 27 SNPs between basepair positions 
61234329 and 61372379 of FADS1 FADS2 could be tagged. The efficiency was 10.7 fold 
even though the two further SNPs rs174561 and rs3834458 could not be included as these 
are not included in the HapMap database. Genotyping of SNPs was realized with the iPLEX 
(Sequenom, San Diego, CA, USA) method by means of matrix assisted laser desorption 
ionization-time of flight mass spectrometry method (MALDI-TOF MS, Mass Array; Sequenom) 
according to the manufacturer’s instructions. Standard genotyping quality control included 
10 % duplicate and negative samples. Genotyping discordance rate was below 0.3 %. 
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Statistical analysis 
For the studied subpopulation allele frequencies and Fisher’s exact test of Hardy-Weinberg-
Equilibrium were conducted with procedure “proc allele” of the statistical software module 
SAS/GENETICS of SAS version 9.1.3. Lewontin’s D’ and pairwise-squared correlations r2 
were calculated with the software JLIN [23] to examine linkage disequilibrium.  
FA data are presented as medians and interquartile ranges (IQR, ranges from the 1st to the 
3rd quartile), since FA with very low concentrations showed skewed distributions. 
Level of tracking between FA data obtained at the two time points was estimated by 
Spearman correlation. This is the simplest way for continuous outcome variables to asses 
tracking between two measurements [24]. Furthermore, Spearman correlation coefficients 
were calculated for the single SNPs applying an additive model where homozygous minor 
allele carriers were coded as 2, heterozygous coded as 1, and homozygous major allele 
carriers coded as 0 (= reference category). Spearman correlations were performed using the 
statistical software PASW Statistics, version 18.0.0. 
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Results 
Baseline characteristics for the total study population and for the studied subpopulation of the 
LISA Munich cohort are listed in Table 1. Weight, height and BMI are comparable between 
the total and the subpopulation. However, the percentage of boys, fully breastfeeding and 
high maternal education is somewhat higher and the proportion of maternal smoking during 
pregnancy is slightly lower in the studied subpopulation.  
Information regarding position, possible functional region, genotyping frequencies and P-
values of Fisher’s exact test for violation of Hardy-Weinberg-Equilibrium for the five analyzed 
SNPs of the FADS1 FADS2 gene cluster are given in Table 2. The minimum P-value for any 
of the five analyzed SNPs was 0.69 (rs174556 and rs174561).  
Lewontin’s D’ and pairwise-squared correlations r2 for the studied subpopulation are shown in 
Figure 2. Lewontin’s D’ ranged between 0.97 and 1.0 and the pairwise-squared correlations 
r2 ranged between 0.87 and 1.0, confirming that all five SNPs are in high linkage 
disequilibrium. 
 
Fatty acid composition of serum GP 
Five FA, namely the saturated FA palmitic (C16:0) and stearic acid (C18:0), the 
monounsaturated FA oleic acid (C18:1n-9) and the two n-6 PUFA linoleic acid (LA, C18:2n-6) 
and arachidonic acid (AA, C20:4n-6), showed the highest concentrations in serum GP and 
accounted for more than 85 % of total GP FA (Supporting Table 1). Up to 45 % of all serum 
GP FA were saturated, ~40 % were polyunsaturated, and ~15 % were monounsaturated. 
Trans FA were found in minor quantities, contributing less than 0.5 % to total GP FA. The 
abundance of n-6 PUFA was ~7 times higher than that of n-3 PUFA in GP.  
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Concentrations of total saturated fatty acids (SFA), total monounsaturated fatty acids (MUFA) 
and PUFA were higher at 6 years compared to 2 years, while the concentration of total trans 
FA did not differ with time. Percentage values did not differ significantly between both time 
points. However, the PUFA/SFA ratio increased from 0.92 at 2 years to 0.96 at 6 years. N-6 
PUFA showed higher values at 6 years compared to 2 years, while n-3 PUFA values 
remained constant. The n6/n3 ratio increased from 7.5 to 8.2 over time.  
Changes in concentrations of individual FA or groups of FA were positively correlated with 
each other for most FA (data not shown), e.g. changes of LA concentrations from 2 to 6 years 
were highly correlated with changes of the concentrations of total SFA (0.71***), total MUFA 
(0.49***), C18:3n-6 (0.30***), C20:3n-6 (0.25***), C20:4n-6 (0.41***) and C18:3n-3 (0.43***). 
For percentage values changes in LA were negatively correlated with the changes in the 
percentage values of total SFA             (-0.50***), total MUFA (-0.40***), C20:3n-6 (-0.45***), 
C20:4n-6 (-0.34***), C20:5n-3 (-0.35***), and C22:6n-3 (-0.37***). Besides the correlation with 
LA, total SFA and total MUFA percentage values were not correlated with other FA 
percentage values (data not shown). The changes of total SFA concentrations over time were 
highly correlated with the changes of total MUFA concentrations (r = 0.79***, Figure 3a), 
whereas no correlation was observed between the changes of total SFA and total MUFA 
percentages over the four year period (r = -0.02, Figure 3b). 
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Tracking 
For most FA the percentage contributions and concentrations (Supporting Table 1) at the 
age of 2 years were significantly correlated to those at 6 years. FA concentrations were 
stronger correlated between both time points than FA percentage contributions. The highest 
correlations between both time points were observed for the n-6 LC-PUFA dihomo-gamma-
linolenic acid (DGLA, C20:3n-6), AA and docosapentaenoic acid (DPA, C22:5n-6) for both, 
concentrations and percentage values.  
Moderate tracking (0.6 > r > 0.4) was observed for the percentage values of four FA (C17:0, 
C20:3n-6, C20:4n-6, and C22:5n-6) and for the concentrations of six FA (C17:0, C18:0, 
C20:3n-6, C20:4n-6, C22:5n-6, and C22:5n-3), respectively. The majority of all analyzed FA 
showed low or no tracking (r < 0.4).  
Concentrations of SFA in serum GP showed a higher degree of tracking than their 
corresponding percentage values. Interestingly, total SFA percentage values showed no 
correlation whereas single SFA showed low to moderate tracking. For n-6 PUFA moderate 
correlations between both time points were observed, with the highest correlations for DGLA, 
and weaker correlations for their precursor FA LA and gamma-linoleic acid (GLA, C18:3n-6). 
Tracking of n-3 PUFA was markedly lower than that of n-6 PUFA, with lower tracking rates for 
the precursor n-3 PUFA compared to their longer chain derivates. Similar findings were 
observed for n-9 FA. Percentage values of mead acid (20:3n-9) were higher correlated 
between both time points (r = 0.39) than those of oleic acid (r = 0.22), a precursor of mead 
acid. Trans FA and MUFA had weak correlations.  
The ratio of the n-6 PUFA AA/LA showed a moderate degree of tracking (r = 0.41), and the 
ratio remained practically constant over the 4 year period with 0.42 ± 0.13 at 2 years, and 
0.40 ± 0.11 at 6 years, respectively. There was an increasing trend over time for the n-3 
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PUFA ratios EPA/ALA (2 years: 2.31 ± 1.27; 6 years: 2.50 ± 1.51) and DHA/ALA (2 years: 
12.72 ± 8.23; 6 years: 13.58 ± 8.34). Compared to the n-6 PUFA ratio of AA/LA somewhat 
lower tracking levels were observed for the n-3 PUFA ratios EPA/ALA (r = 0.20) and 
DHA/ALA (r = 0.20), respectively. 
 
Influence of FADS polymorphisms on tracking 
We found that tracking of n-6 LC-PUFA concentrations (except for C22:4n-6) was higher for 
homozygous and heterozygous carriers of minor alleles in the five analyzed SNPs than for 
homozygous carriers of major alleles (Supporting Table 2). In contrast, tracking of n-6 LC-
PUFA compositions showed no clear trend. For total n-3 LC-PUFA concentrations and 
compositions, minor allele carriers had a lower tracking compared to homozygous major allele 
carriers but individual n-3 LC-PUFA showed no consistent trend. Tracking of C20:3n-3 and 
EPA was lower in minor allele carriers than in carriers homozygous for the major allele, 
whereas results for C22:5n-3 were inconsistent. For DHA tracking was comparable between 
the 3 groups in all analyzed SNPs.  
5. PUBLICATION 4 
 
 53 
Discussion 
Fatty acid status 
We found increasing serum GP total FA concentrations over the 4-year follow-up. The 
children studied had higher serum PUFA concentrations at the age of 6 than at 2 years, 
whereas SFA and MUFA concentrations showed only a slight increase over time. Hence, the 
PUFA/SFA ratio increased with age. These observations point towards a change in food 
habits with a shift to higher proportions of polyunsaturated dietary fat. Our findings are in 
accordance with observations from Guerra et al. [19] who found an increase of plasma 
phospholipid PUFA/SFA ratio in 26 Portuguese children from 2 to 5 years of age.  
Plasma GP n-6 PUFA concentrations increased during the follow-up, which likely reflects a 
higher intake of foods providing LA or AA (e.g. vegetable oils, eggs, meat and meat products) 
at older age [25]. In contrast, plasma concentrations of n-3 PUFA remained almost constant 
over time. This is presumably attributable to a low consumption of n-3 PUFA in the diets of 
most German children. The main dietary sources of n-3 LC-PUFA are fish and other seafood. 
Children who like to eat fish and whose parents pay attention to a regular fish intake are likely 
to maintain such habits over time, and a relatively high n-3 LC-PUFA level will persist; 
whereas children who tend not to eat fish retain a low n-3 LC-PUFA level. Our findings 
suggest that only few children change their food habits with regard to fish intake over time.  
The strong positive correlation between the changes in the concentrations of total MUFA and 
total SFA, points towards a strong influence of lipid metabolism on FA concentrations. This 
assumption is strengthened by the absence of a correlation between changes in the 
percentage values of total MUFA and total SFA, as well as previous findings of Moilanen et al. 
[26] who reported a significant association between serum cholesteryl ester FA composition 
and various serum lipids.  
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LA values seem to have a strong influence on the percentage composition of serum GP FA, 
whereas the impact of SFA and MUFA on FA composition is very low. The correlations 
between the changes in FA percentages over the 4-year period indicate that the changes in 
LA mainly affected SFA and MUFA. We found negative correlations of LA with C20:3n-6, 
C20:4n-6, C20:5n-3 and C22:6n-3, which was in accordance with previous findings [27]. 
 
Tracking 
Tracking of FA percentage values in plasma or serum phospholipids and cholesteryl esters 
has previously been reported in children and adults [17-19,27], but tracking of FA 
concentrations has not been investigated before. Our results revealed tracking rates of similar 
magnitude compared to findings of Guerra et al. [19] for total SFA (0.02/-0.02, our 
results/Guerra et al.) and total MUFA (0.22/0.25), whereas n-6 LC-PUFA (0.35/0.63) and n-3 
LC-PUFA (0.23/0.31) showed a somewhat lower tracking in our study. This might be 
explained by the different study settings. Guerra et al. examined tracking of plasma 
phospholipid FA in 26 Portuguese children between the age of 2 and 5 years, whereas we 
examined tracking of FA in serum GP (a subgroup of phospholipids) in a larger group of 331 
German children between the ages of 2 and 6 years. Previous publications show that tracking 
of plasma cholesteryl ester FA is higher than that of plasma phospholipid FA, and that FA 
tracking might be higher in adults than in children [17-18,28]. However, independent from the 
studied subjects and the analyzed lipid fraction, our results are consistent with previously 
published data on FA tracking in that n-6 LC-PUFA showed greater tracking than n-3 LC-
PUFA, and that LA and ALA have a lower degree of tracking than their LC-PUFA derivates. 
We also determined tracking of FA concentrations, which turned out to be somewhat greater 
than the tracking of FA percentages, particularly for SFA. This further supports that lipid 
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metabolism might have a significant influence on serum GP FA concentrations. The high 
tracking of C17:0, which reflects the intake of dairy fats, might indicate a stable dietary milk 
and dairy product intake. Patterson et al. [29] reported a tracking correlation coefficient of 0.3 
for dietary intakes of milk and yoghurt in Swedish children over a period of 6 years.  
Our hypothesis that carriers of the major allele show higher tracking than carriers of at least 
one minor allele could be confirmed only for serum GP total n-3 LC-PUFA levels. For 
individual n-3 PUFA this trend is not consistent. In contrast to our expectation, tracking of total 
n-6 LC-PUFA percentage and concentration values was lower in subjects homozygous for the 
major allele than in subjects carrying one minor allele. However, tracking values were 
comparable between carriers homozygous for the major allele and carriers homozygous for 
the minor allele, except for SNP rs3834458, here tracking values of subjects homozygous for 
the minor allele were comparable with theses of subjects carrying one minor and one major 
allele. 
We assume that the major portion of serum GP n-6 LC-PUFA levels are contributed by 
endogenous synthesis via the desaturase/elongase pathway, which was shown to be largely 
influenced by genetic variants in the FADS1 FADS2 gene cluster [11]. Linoleic acid, the n-6 
LC-PUFA precursor, is the most abundant PUFA in diet and serum lipids. Serum GP LA 
values are largely determined by dietary intake. In our study we found an increase of LA 
levels over time and only slight tracking for LA values. Thus, subjects with higher LA 
conversion rates have a higher variability in n-6 LC-PUFA levels depending on available LA 
and therefore tend to show a lower tracking. The hypothesized association of higher tracking 
with higher conversion intensity can only be observed for very low precursor levels, as is the 
case for n-3 PUFA.  
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In conclusion, the present study documents low to moderate tracking of serum GP FA 
composition over a period of 4-years. The highest tracking was observed for n-6 LC-PUFA. 
Furthermore, LC-PUFA metabolites have a higher tracking than their precursor FA. We found 
that FADS1 FADS2 gene variants modulate tracking of serum GP PUFA levels. However, 
results are inconsistent and the influence of general lipid and lipoprotein metabolism seems to 
be more pronounced than the influence of FA specific pathways. As a consequence FA 
concentrations show a higher degree of tracking than FA percentage values.  
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FIGURE LEGEND 
 
Figure 1. Analyzed serum samples and genetic measurements from the Munich LISA 
cohort. 
 
Figure 2. Pair wise linkage disequilibrium measured by Lewontin’s D’ and r2 for the 
common five single nucleotide polymorphisms (SNP) in the studied subpopulation 
(n=331) of the LISA Munich cohort. 
 
Figure 3. Changes of total monounsaturated fatty acids between 2 and 6 years (delta 
MUFA, mg/l) show a high correlation (r = 0.79) with changes of total saturated fatty 
acids (delta SFA, mg/l) (a), while changes of corresponding percentage values (%) are 
unrelated (b, r = -0.02). 
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7. Summary 
Objectives: Clinical and epidemiological studies show that the plasma FA composition, a 
marker of FA status and dietary intake, is associated with health outcomes on a short and 
long term basis. Detailed investigation of the relationships between plasma FA composition 
and health requires the analysis of high numbers of samples, which is often limited by 
laborious sample preparation procedures. The objective of this work was to develop high-
throughput methods which enable simple, precise and inexpensive analysis of plasma and 
serum GP FA composition and plasma total lipid FA composition. For serum GP FA 
composition, reference values for children were provided using the newly developed 
methodology. The tracking behavior of serum GP FA composition and concentrations in 
children was investigated. Furthermore, the potential influence of FADS gene variants on 
tracking, which has not been investigated so far, was determined. 
Methods: For the analysis of GP FA composition only protein precipitation and subsequent 
base catalyzed methyl ester synthesis are required. The plasma total lipid FA are in situ 
transferred into methyl esters, avoiding initial extraction and drying steps. Identical gas 
chromatographic conditions can be applied for both methods. The GP FA composition of 
1326 serum samples obtained from a cohort of 951 children at 2 and 6 years, participating in 
an ongoing birth cohort study, was analyzed with the newly developed high-throughput 
method. Data were used to provide reference values. From 331 children samples were 
available at both time points (2 and 6 years) and used to assess tracking. Spearman 
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correlation coefficients were estimated to describe tracking of FA compositions and 
concentrations over 4-years and to assess the influence of FADS gene variants (rs174545, 
rs174546, rs174556, rs174561, rs3834458) on FA tracking. 
Results: Coefficients of variation for FA contributing more than 1 % to total FA were below     
4 % for both methods. The results showed good agreement with FA values obtained by 
standard reference methods. FA values in serum GP were in very good agreement with other 
published values in serum or plasma PL for most of the analyzed FA. No major age and 
gender differences in GP FA composition were observed. For most FA compositions and 
concentrations at 2 and 6 years were significantly correlated, with correlation coefficients from 
0.12 to 0.49. FA concentrations correlated more closely than FA compositions. Concentration 
changes of total monounsaturated FA and total saturated FA over time correlated closely       
(r = 0.79) but percentage values were unrelated (r = -0.02). Tracking for n-6 LC-PUFA 
concentrations was lower in subjects homozygous for the major allele of FADS variants, and 
higher in carriers of at least one minor allele, whereas for n-3 LC-PUFA this was vice versa. 
Conclusions: The newly developed methods enable the precise quantification of 25 FA 
(including arachidonic, eicosapentaenoic and docosahexaenoic acid) while reducing the 
manual work load to about 10 % compared to standard reference methods. Samples from 
infants can be assessed as the required plasma volume is very low. The methods are simple, 
robust and well suitable for the application in large clinical trials and epidemiological studies. 
The serum GP FA values obtained from children aged 2 and 6 years may serve as reference 
values in clinical routine, e.g. for monitoring and improving therapeutic interventions. 
Furthermore, they can serve as a reference for interpreting FA values in clinical and 
epidemiological studies. Serum GP FA composition shows tracking over 4-years particularly 
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for n-6 PUFA, with a higher tracking for LC-PUFA metabolites than for their precursor PUFA. 
Lipid and lipoprotein metabolism seem to have a stronger influence on serum FA levels and 
tracking than FA specific metabolic pathways. 
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8. Zusammenfassung 
Ziele: Klinische und epidemiologische Studien zeigen, dass die Plasma-Fettsäure(FS)-
Zusammensetzung, ein Marker für den Fettsäurestatus und die Ernährung, sowohl mit der 
kurz- als auch mit der langfristigen Verbesserung des Gesundheitszustandes in Zusammen-
hang steht. Detaillierte Untersuchungen der Zusammenhänge zwischen der Plasma-FS-
Zusammensetzung und der Gesundheit erfordern Analysen großer Probenzahlen, welche 
oftmals durch aufwendige Probenaufarbeitungsprozeduren begrenzt sind. Ziel dieser Arbeit 
war die Entwicklung von Hochdurchsatzmethoden, die eine einfache, präzise und 
kostengünstige Analyse der Plasma- und Serum-Glycerophospholipid(GP)-FS-
Zusammensetzung und der Plasma Gesamtlipid-FS-Zusammensetzung ermöglichen. Für die 
Serum-GP-FS-Zusammensetzung wurden Referenzwerte für Kinder mit Hilfe der 
neuentwickelten Methode ermittelt. Das Spurhalten der Serum-GP-FS-Zusammensetzung 
und –Konzentrationen wurde in Kindern untersucht. Weiterhin wurde der potentielle Einfluss 
von FADS-Genvarianten auf das Spurhalten untersucht, was bisher nicht erforscht ist. 
Methoden: Zur Analyse der GP-FS-Zusammensetzung werden nur eine Fällung der Proteine 
und eine anschließende basenkatalysierte Methylestersynthese benötigt. Die Plasma-
Gesamtlipid-FS werden in situ in Methylester überführt, wobei vorangehende Extraktions- und 
Trocknungsschritte vermieden werden. Identische gaschromatographische Bedingungen 
können für beide Methoden verwendet werden. Die GP-FS-Zusammensetzung von 1326 
Serumproben, erhalten aus einer Kohorte von 951 Kindern bei 2 und 6 Jahren, die in einer 
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fortlaufenden Geburtskohortenstudie teilnehmen, wurde mit der neuentwickelten 
Hochdurchsatzmethode analysiert. Die Daten wurden zur Bereitstellung von Referenzwerten 
verwendet. Von 331 Kindern waren Proben von beiden Zeitpunkten (2 und 6 Jahre) erhältlich 
und wurden verwendet, um das Spurhalten zu bestimmen. Spearmans Korrelations-
koeffizienten wurden ermittelt, um das Spurhalten der FS-Zusammensetzung und                       
-Konzentrationen über 4 Jahre und den Einfluss von FADS-Genvarianten (rs174545, 
rs174546, rs174556, rs174561, rs3834458) auf das Spurhalten zu bestimmen.  
Ergebnisse: Variationskoeffizienten der Fettsäuren, welche mehr als 1 % zu den 
Gesamtfettsäuren beitrugen, lagen unter 4 % bei beiden Methoden. Die Ergebnisse zeigten 
eine gute Übereinstimmung mit FS-Werte gemessen mit Standard-Referenzmethoden. Die 
Fettsäurewerte in Serum-GP waren in sehr guter Übereinstimmung mit anderen publizierten 
Werten in Serum- oder Plasma-Phospholipiden für die meisten analysierten FS. Es wurden 
keine wesentlichen Alters- und Geschlechtsunterschiede in der GP-FS-Zusammensetzung 
beobachtet. Die meisten FS-Zusammensetzungen und –Konzentrationen bei 2 und 6 Jahren 
korrelierten signifikant mit Korrelationskoeffizienten von 0,12 bis 0,49. Die FS-
Konzentrationen waren stärker korreliert als die FS-Zusammensetzungen. Die 
Konzentrationsänderungen über die Zeit der gesamten einfach ungesättigten FS und der 
gesamten gesättigten FS korrelierten stark (r=0,79), wohingegen die prozentualen Werte 
nicht zusammenhingen (r=-0,02). Das Spurhalten der von n-6 LC-PUFA Konzantrationen war 
geringer in Probanden welche homozygot für das Hauptallel der FADS-Varianten waren und 
größer in Trägern von mindestens einem Unterallel, während dies für n-3 LC-PUFA 
umgekehrt war.  
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Schlussfolgerungen: Die neuentwickelten Methoden erlauben die präzise Quantifizierung von 
25 FS (einschließlich Arachidon-, Eicosapentaen- und Dokosahexaensäure) während der 
manuelle Arbeitsaufwand auf ungefähr 10 % reduziert wurde im Vergleich zu Standard-
Referenzmethoden. Proben von Kleinkindern können untersucht werden, da das benötigte 
Plasmavolumen sehr klein ist. Die Methoden sind einfach, robust und sehr gut einsetzbar in 
großen klinischen und epidemiologischen Studien. Die Serum-GP-FS Werte erhalten von 
Kindern im Alter von 2 und 6 Jahren können als Referenzwerte in der klinische Routine, z.B. 
zur Überwachung und Verbesserung therapeutischer Eingriffe dienen. Weiterhin können sie 
als Referenzen zur Interpretation von FS Werten in klinischen und epidemiologischen Studien 
dienen. Die Serum-GP-FS-Zusammensetzung zeigt Spurhalten über 4 Jahre besonders für  
n-6 mehrfach ungesättigte FS mit einem höheren Spurhalten für die langkettigen Metabolite 
als für ihre Vorläufer FS. Der Lipid- und Lipoproteinmetabolismus scheint einen stärkeren 
Einfluss auf die Serum-FS Werte und das Spurhalten zu haben als FS spezifische 
Stoffwechselwege.  
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